A $45 Million Reminder

01 /The Concept

A medication reminder app sounds like the kind of product that raises a few hundred thousand dollars from angel investors and then quietly disappears. Sempre Health has raised $45.5 million. The difference is entirely in the business model.

Sempre Health rewards patients for taking their medications on schedule. The mechanic is straightforward: the app tracks when a user reorders a prescription based on the expected days-of-supply, infers adherence from reorder timing, and unlocks progressively larger discounts on future purchases for users who stay consistent. A patient who maintains adherence for a full year can save 45–65% on their medication costs.

The channel for user acquisition is not direct-to-consumer advertising. Sempre Health partners with insurance companies – specifically those offering prescription drug coverage plans – to offer the app as a free benefit at enrollment. The logic for insurers is clean: policyholders who take their medications consistently see the value of their plan directly, renew at higher rates, and generate better health outcomes that reduce downstream claims costs. Sempre reports a 3.7x ROI for insurer partners on the cost of subsidizing the app.

Pharmaceutical manufacturers are the second revenue partner. Drugmakers have an obvious interest in consistent adherence – a patient who takes a chronic condition medication daily consumes roughly 30x the annual volume of a patient who takes it intermittently. Manufacturers provide discounts through the platform to adherent patients; those discounts attract and retain users; Sempre keeps a margin on the discount flow. Manufacturers report 4–5x ROI on their participation.

This latest round – $20 million – brings total funding to $45.5 million across five rounds.

02 /Why It Matters

Sempre Health is currently focused on cardiovascular, respiratory, and diabetes medications. What those categories share is that they treat chronic conditions: diseases that cannot be cured, only managed, requiring medication for the patient's entire life. That makes the lifetime value of an adherent Sempre user exceptionally high – particularly because the app creates the adherence habit through financial incentive rather than nagging.

The addressable population is larger than it sounds. Nearly 60% of Americans have at least one chronic condition. In absolute terms, that number has grown from 125 million in 2000 to 157 million in 2020 and is projected to reach 171 million by 2030. The trend is structural: people are living longer with conditions that previous generations did not survive long enough to manage chronically.

Sempre is not the only company to identify this opportunity. Elfie, [covered previously](/review/dlja-3-milliardov-chelovek-na-vsju-zhizn), raised $5 million building a rewards-for-health-behavior app that extends the chronic condition concept to weight management and stress. Elfie's product is considerably more feature-heavy – an AI health assistant, a drug database, broader condition coverage – while Sempre's is deliberately minimal: just medication adherence, two partner categories, and direct financial reward. Elfie also distributes through employers rather than insurers, targeting the same underlying population through a different organizational channel.

A [related review](/review/bolee-jeffektivnyj-sposob-prodavat-poleznye-veshhi) covered Bold, a fitness platform for older adults that similarly pivoted from direct consumer sales to insurance distribution – Medicare now covers Bold's platform as a fall-prevention benefit, generating its largest user cohort. The pattern across Sempre, Elfie, and Bold is identical: a health behavior that benefits the individual is difficult to sell to individuals, but straightforward to sell to the organizations that bear the financial cost of the behavior's absence.

Sempre's adherence data shows the compounding effect over time is striking. At the 20th refill, adherent Sempre users refill on schedule at a 75% rate versus 20% for non-users – a gap that widens with every additional refill cycle, making long-tenure users disproportionately valuable to both insurer and manufacturer partners.

03 /Opportunities

The health-tech opportunity that Sempre, Elfie, and Bold collectively illustrate is not about building consumer wellness apps. It is about identifying health behaviors with measurable downstream financial value to institutional payers – insurers, employers, Medicare – and building B2B distribution around that value proposition.

The B2C approach to health behavior change has poor economics: customer acquisition is expensive, willingness to pay is low, and churn is high because the benefit is diffuse and long-term. Flipping the model means selling to an insurer or employer who already has the relationship and the financial stake, and whose existing infrastructure becomes the distribution channel.

Sempre's model is particularly clean in execution. The patient population is clearly defined – chronic condition sufferers requiring lifelong medication. The partner categories are limited to two and both have quantifiable ROI. The user value proposition is concrete – actual dollar savings on purchases they are already making. No abstract wellness benefit to explain, no behavior change that requires persuasion.

For a team considering this space, the entry angle is identifying a chronic condition category with high medication costs, high non-adherence rates, and established insurer or employer coverage relationships to leverage for distribution. The mechanism Sempre has proven can be applied wherever those three conditions hold.